Quince Therapeutics, Inc. Annual Operating Income (Loss) in USD from 2018 to 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Quince Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2018 to 2024.
  • Quince Therapeutics, Inc. Operating Income (Loss) for the quarter ending December 31, 2024 was -$12M, a 20.3% decline year-over-year.
  • Quince Therapeutics, Inc. Operating Income (Loss) for the twelve months ending December 31, 2024 was -$57.3M, a 65.5% decline year-over-year.
  • Quince Therapeutics, Inc. annual Operating Income (Loss) for 2024 was -$57.3M, a 65.5% decline from 2023.
  • Quince Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$34.6M, a 33.4% increase from 2022.
  • Quince Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$52M, a 42.4% increase from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$57.3M -$22.7M -65.5% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-24
2023 -$34.6M +$17.4M +33.4% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-24
2022 -$52M +$38.3M +42.4% Jan 1, 2022 Dec 31, 2022 10-K 2024-04-01
2021 -$90.3M -$11.4M -14.5% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-15
2020 -$78.9M -$39.7M -101% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-01
2019 -$39.2M -$27M -223% Jan 1, 2019 Dec 31, 2019 10-K 2022-03-01
2018 -$12.1M Jan 1, 2018 Dec 31, 2018 10-K 2021-03-01
* An asterisk sign (*) next to the value indicates that the value is likely invalid.